<DOC>
	<DOCNO>NCT02704533</DOCNO>
	<brief_summary>MAVACHE sequential dose schedule optimization trial intravenous immunization PfSPZ Vaccine 18 54 malaria-naïve , healthy adult volunteer receive 9x10^5 , 1.35x10^6 , 2.7x10^6 PfSPZ per dose total dose 2.7x10^6 8.1x10^6 PfSPZ follow CHMI 3,200 fully infectious PfSPZ ( PfSPZ Challenge ) . PfSPZ Challenge ( 7G8 ) ass vaccine efficacy , safety , tolerability infectivity ascend PfSPZ dos assess healthy , malaria-naïve volunteer .</brief_summary>
	<brief_title>Sequential Optimization Dose Schedule PfSPZ Vaccine</brief_title>
	<detailed_description>The study take place Institut für Tropenmedizin , Eberhard Karls Universität Tübingen , Tübingen Germany . The study two phase : 1 ) dose optimization , 2 ) regimen verification . In first phase group A , B1 , B2 , C1 , C2 C3 vaccinate sequentially pre-specified order , follow homologous CHMI 3,200 PfSPZ Challenge ( NF54 ) three week last vaccine injection . Dose optimization phase A : 9x10^5 PfSPZ Days 0 , 7 28 ( n = 6 ) B1 : 1.35x10^6 PfSPZ Days 0 7 ( n = 6 ) B2 : 1.35x10^6 PfSPZ Days 0 , 7 , 28 ( n = 6 ) C1 : 2.7x10^6 PfSPZ Day 0 ( n = 6 ) C2 : 2.7x10^6 PfSPZ Day 0 7 ( n = 6 ) C3 : 2.7x10^6 PfSPZ Days 0 , 7 28 ( n = 6 ) In parallel CHMI PfSPZ Challenge ( NF54 ) optimization phase , total nine volunteer receive either 800 , 1,600 3,200 PfSPZ Challenge ( 7G8 ) ( PfSPZ Challenge ( 7G8 ) dose find ) ass safety , tolerability infectivity PfSPZ Challenge ( 7G8 ) malaria-naïve healthy adult volunteer . PfSPZ Challenge ( 7G8 ) dose finding/infection D1 : 800 PfSPZ ( n = 3 ) D2 : 1,600 PfSPZ ( n = 3 ) D3 : 3,200 PfSPZ ( n = 3 ) Subsequently , short efficacious regimen ( V1 ) three-dose regimen ( Day 0 , 7 28 ) high safe dose ( V2 ) select verified placebo ( normal saline ( NS ) ) . Groups V1 V2 vaccinate approximately time undergo repeat CHMI three eight week last immunization . Volunteers either receive PfSPZ Vaccine NS placebo . Allocation random double blind . Repeat CHMI do PfSPZ Challenge ( NF54 ) PfSPZ Challenge ( 7G8 ) , give randomized sequence . All immunization give direct venous inoculation ( DVI ) . Regimen verification phase V1 : Shortest efficacious regimen ( n = 12 ) placebo ( n = 6 ) V2 : Maximum regimen ( n = 12 ) placebo ( n = 6 ) P1 : Placebo V1 group ( n=6 ) P2 Placebo V2 group ( n=6 )</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult age 18 45 year Able willing ( Investigator 's opinion ) comply study requirement Willing allow investigator discuss volunteer 's medical history general practitioner ( 'Hausarzt ' German ) require Residence Tübingen surroundings period trial Women : Must agree practice continuous effective contraception duration study ( method result failure rate le 1 % per year ) Agreement refrain blood donation course study end involvement study accord local national blood banking eligibility criterion ( currently four year restriction Germany ) Written inform consent receive PfSPZ product : Optimization phase : PfSPZ Vaccine immunization PfSPZ Challenge ( NF54 ) CHMI PfSPZ Challenge ( 7G8 ) dose finding : PfSPZ Challenge ( 7G8 ) CHMI Verification phase : PfSPZ Vaccine immunization , PfSPZ Challenge ( NF54 ) PfSPZ Challenge ( 7G8 ) CHMI Reachable ( 24/7 ) mobile phone immunization CHMI period Willingness take curative antimalarial regimen follow CHMI Agreement stay overnight observation period intensive followup postchallenge require Answer question inform consent quiz correctly A body mass index &lt; 35 History P. falciparum malaria Planned travel malaria endemic area end CHMI ( 28 day CHMI ) Use systemic antibiotic know antimalarial activity within 30 day study enrollment ( e.g . trimethoprimsulfamethoxazole , doxycycline , tetracycline , clindamycin , erythromycin , fluoroquinolones , azithromycin ) Receipt investigational product 30 day precede enrollment , plan receipt study period Prior receipt malaria vaccine Immunization three vaccine within past four week HIV infection Any confirm suspected immunosuppressive immunodeficient state , asplenia , recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) Use immunoglobulins blood product within 3 month prior enrolment Known suspect hemolytic disease presence hemoglobinopathy Pregnancy , lactation intention become pregnant study Contraindications use follow antimalarial medication : atovaquoneproguanil , artemetherlumefantrine mefloquine History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) History serious psychiatric condition may affect participation study ( include restrict organic , include symptomatic , mental disorder [ ICD10 code : F00F09 ] , schizophrenia , schizotypal delusional disorder [ F20F29 ] , mood ( affective ) disorder [ F30F39 ] , mental retardation [ F70F79 ] , Disorders psychological development [ F80F89 ] psychiatric condition require hospitalization psychiatric treatment extended period ) . Any serious chronic illness require hospital specialist supervision Suspected known current alcohol abuse define alcohol intake great 60 g ( men ) 40 g ( woman ) per day carbohydrate deficient transferrin ( CDT ) level ≥2.5 % Suspected known inject drug abuse 5 year precede enrollment Positive hepatitis B surface antigen ( HBsantigen ) Seropositive hepatitis C virus ( antibody HCV ) Falling moderate risk high category fatal nonfatal cardiovascular event within 5 year ( &gt; 10 % ) determine noninvasive criterion cardiac risk Abnormal electrocardiogram screening : pathologic Q wave significant STT wave change , leave ventricular hypertrophy , clinically significant arrhythmia , leave bundle branch block , secondary tertiary AV heart block A QT/QTcB interval &gt; 450 m Volunteers unable closely follow social , geographic psychological reason Any clinically significant abnormal find biochemistry hematology blood test , urine analysis clinical examination History seizure ( except isolate uncomplicated febrile convulsion childhood ) Any significant disease , disorder finding , opinion investigator , may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>PfSPZ Vaccine</keyword>
	<keyword>PfSPZ Challenge ( NF54 )</keyword>
	<keyword>PfSPZ Challenge ( 7G8 )</keyword>
	<keyword>CHMI</keyword>
</DOC>